Enhanced cleavage of genomic CCR5 using CasX2 Max
- 25 October 2025
- journal article
- Published by Taylor & Francis in RNA Biology
- Vol. 22 (1) , 1-18
Abstract
Development of novel CRISPR/Cas systems enhances opportunities for gene editing to treat infectious diseases, cancer, and genetic disorders. CasX2 (PlmCas12e) belongs to the class II CRISPR system derived from Planctomycetes, a non-pathogenic bacterium present in aquatic and terrestrial soils and offers several advantages as a potential therapeutic CRISPR system over Streptococcus pyogenes Cas9 (SpCas9) and Staphylococcus aureus Cas9 (SaCas9). These advantages include its smaller size, distinct protospacer adjacent motif (PAM) requirements, staggered cleavage cuts that promote homology-directed repair, and the absence of pre-existing immunity in humans. We compared the cleavage efficiency and double-stranded break repair characteristics between CasX2 and CasX2Max, a recently generated CasX2 variant with three amino acid substitutions, for targeting CCR5, a gene that encodes the CCR5 receptor important for HIV-1 infection. Two single guide RNAs (sgRNAs) were designed that flank the 32 bases deleted in the natural CCR5 ∆32 mutation. Nanopore sequencing demonstrated that CasX2 using sgRNAs with spacers of 17 nucleotides (nt), 20 nt or 23 nt in length were ineffective at cleaving genomic CCR5. In contrast, CasX2Max using sgRNAs with 20 nt and 23 nt spacer lengths, enabled cleavage of genomic CCR5. Structural modelling indicated that two of the CasX2Max amino acid substitutions enhanced sgRNA-DNA duplex stability, while the third improved DNA strand alignment within the catalytic site. These structural changes likely underlie the increased activity of CasX2Max in cellular gene excision. In sum, CasX2Max consistently outperformed native CasX2 across all assays and represents a superior gene-editing platform for therapeutic applications.Keywords
Funding Information
- Department of Veterans Affairs
- Genomics and Molecular Biology Shared Resources
- Dartmouth Cancer Center
- NCI Cancer Center Support Grant (5P30 CA023108-41)
This publication has 40 references indexed in Scilit:
- UCSF ChimeraX : Tools for structure building and analysisProtein Science, 2023
- Multiplexed Assembly and Annotation of Synthetic Biology Constructs Using Long-Read Nanopore SequencingACS Synthetic Biology, 2022
- Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editingThe Innovation, 2022
- Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activityMolecular Cell, 2022
- Comprehensive Profiling of Four Base Overhang Ligation Fidelity by T4 DNA Ligase and Application to DNA AssemblyACS Synthetic Biology, 2018
- Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applicationsJournal of Controlled Release, 2017
- Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1Molecular Cell, 2017
- New CRISPR–Cas systems from uncultivated microbesNature, 2016
- Engineered CRISPR-Cas9 nucleases with altered PAM specificitiesNature, 2015
- In vivo genome editing using Staphylococcus aureus Cas9Nature, 2015